And is the government getting wobbly on its objections to the 340B rebate model?
And Dr. Oz had some worthwhile thoughts on PBMs and drug pricing last week
Plus details on the BU game, a link on the state of biotech in Boston, and a poll about what patients and clinicians think about health insurance
Plus a Cuban-vs-Arnold faceoff, a super-cheap biosimilar, and a little NCAA hockey talk
Plus a story about a 340B robot and a 340B analysis that is equal parts intriguing and useless
And copay accumulator bans continue to spread across the country ... but does it matter?
And I have a survey on what conferences you attend ... I’d be grateful for your input
It's a day of quick hits ... here's to a great weekend
Plus a link to the first-ever ‘Launch Price Communication Report’
And Novo moves to start selling Wegovy directly to patients at $499 a month
And quantifying how the move from copays to coinsurance is driving up OOPs on ‘negotiated’ drugs
And Mesoblast unveils the price for its stem-cell therapy with a noteworthy amount of transparency around value
